Maharashtra FDA flags hospital-consumable markups as high as 2,841%

Maharashtra FDA Commissioner Tukaram Mundhe has urged central authorities to examine the gap between hospital procurement prices and MRPs for consumables. An IV infusion set with a trade price of Rs 11.05 was cited with an MRP of Rs 325, raising the prospect of tighter disclosure and pricing rules.

— Source publishedWed, 16 Sept, 2026, 15:41 IST·First seen Wed, 16 Sept, 2026, 16:49 IST·Source NDTV Profit

What happened

Maharashtra Food and Drug Administration · Maharashtra FDA Commissioner Tukaram Mundhe flagged extreme markups on hospital consumables and urged central

Key facts

  • IV infusion set: trade price Rs 11.05; MRP Rs 325; markup 2,841%
  • Syringe: trade price Rs 6.75; MRP Rs 57.20
  • Catheter: trade price Rs 29.41; MRP Rs 310
  • Drugs (Prices Control) Order, 2013

Why this matters

Corporate-development teams should diligence consumables revenue exposure, pricing governance and supplier contracts in any healthcare-services target, as inflated MRP practices could create regulatory and reputational liabilities.

What to watch

  • Central Health Ministry, NPPA, CDSCO or Department of Pharmaceuticals response to Maharashtra FDA's request.
  • Orders requiring hospitals to display procurement price, MRP, patient charge or itemized consumable bills.
  • Expansion of the inquiry from a cited infusion set to broader disposable-device categories.
  • State FDA inspections, notices to hospitals or manufacturers, and consumer-court or public-interest litigation.
  • Hospital-chain announcements of capped markups, zero-markup pharmacies or transparent consumable billing.
  • Evidence of MRP cuts, distributor commission changes or new handling-fee structures.
  • Audit procurement-to-MRP spreads across consumable categories, especially infusion, syringes, catheters, implants and emergency-care supplies.
  • Model exposure to lower MRPs, capped hospital markups and mandatory itemized billing; separate manufacturer, distributor and hospital margin effects.
  • Prepare revised packaging, price-list and billing-data systems that can substantiate trade price, MRP, tax and patient charge.
  • Accelerate private-label and direct-procurement programs only where quality certification and traceability can withstand regulatory review.
  • Engage hospital chains and group-purchasing organizations on transparent contracted pricing and volume commitments.